SLCTR/2021/029招募中2 期
A single arm phase II clinical trial to assess safety, efficacy and feasibility of Polyethylene Glycol (PEG) fusion in nerve repair following acute transection of median and/or ulnar nerves in adults
Dr. Gayan Ekanayake0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a.Age 18 years to 60 years
- •b. Both males and females
- •c.Admitted to accident and orthopedic services department of National Hospital of Sri Lanka
- •d.Sustaining single complete cut injury to median and/or ulnar nerve at forearm (defined as the nerve is cut at or in between distal wrist crease and elbow flexion crease due to a sharp cutting mechanism. e.g., glass, sword, sharp knife)
- •e.Nerve repair performed within 72 hours from the time of injury
排除标准
- •a.Patients who are unable to provide valid informed consent
- •b.Patients sustaining injury to both radial and ulnar arteries in addition to nerve injury
- •c.Patients sustaining simultaneous bilateral upper limb nerve/ tendon injury
- •d.Patients with any past history of significant injury or disability of contralateral upper limb
研究者
相似试验
已完成
2 期
Phase II clinical trial of Angipars in patients with diabetic foot ulcer in SyriaIRCT201102204272N2Pars Roos Biotechnology Co.30
已完成
不适用
A prospective trial investigating the safety and efficacy of dose-escalated radiotherapy for men with prostate cancer following insertion of a gel spacer between the prostate and rectumProstate CancerACTRN12621000056897Epworth HealthCare71
进行中（未招募）
不适用
A phase II, double-blind study to evaluate the safety, reactogenicity and immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a booster dose in healthy young adults previously vaccinated in the primary vaccination study SPNG-001 (111651). - SPNG-006 BST:001EUCTR2009-011022-33-BEGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of SOT102 as a single drug or in combination with standard of care treatment, in patients with stomach and pancreas cancerGastric and pancreatic adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2021-005873-25-ESSOTIO Biotech a.s.269
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of SOT102 as a single drug or in combination with standard of care treatment, in patients with stomach and pancreas cancerGastric and pancreatic adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2021-005873-25-BESOTIO Biotech a.s.269